Sun's takeover of Ranbaxy may hurt competition: CCI

Tags: News
India's antitrust regulator said on Thursday it had made an initial observation that Sun Pharmaceutical Industries Ltd's agreed $3.2 billion acquisition of Ranbaxy Laboratories Ltd could hurt competition, asking the companies to provide more details.

The Competition Commission of India (CCI) is still investigating the deal, but has formed a "prima facie opinion that the combination is likely to have an appreciable adverse effect on competition", according to a government statement on Thursday and a document posted on the regulator's website.

Sun and Ranbaxy have been asked by the regulator to publish details of the deal within 10 working days on their websites as well as in four national newspapers. The CCI also sought comments or objections from the public on the proposed deal.

Sun Pharma agreed in April to buy Ranbaxy from Japan's Daiichi Sankyo Ltd to create the world's fifth-largest maker of generic drugs. Both companies have previously said they expect to complete the deal by December.

EDITORIAL OF THE DAY

  • Do we need a new yardstick to gauge our prosperity?

    While we in India are trying to clear the cobwebs of confusion about how best to calculate gross domestic product (GDP) growth statistics, at the best

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Susan Visvanathan

A world that is constantly at war

THE 19th century posed specific problems to theorists about how ...

Rajgopal Nidamboor

Let’s find the power within & transform

It goes without saying that we are in the midst ...

Shona Adhikari

Masterpieces on the auction block

A rather important auction of 20th century Indian art by ...